Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 3,666 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Non-Small Cell Lung Cancer, Small Cell Lung Cancer Clear all
Terminated Phase 1 Interventional Results available

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

NCT05267470
View directory record Official record
Conditions
Squamous-Cell Non-Small-Cell Lung Cancer
Interventions
Bemarituzumab, Docetaxel, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Orange, California • Morristown, New Jersey • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-930
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer

NCT00003831
View directory record Official record
Conditions
Lung Cancer
Interventions
conventional surgery
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
70
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 21, 2026, 10:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
View directory record Official record
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated No phase listed Observational

A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing

NCT02705404
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma Non-small-cell Lung
Interventions
Multifocal Tissue Banking
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 21, 2026, 10:58 AM EDT
Withdrawn Phase 1 Interventional

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

NCT01637376
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell-Lung
Interventions
Temoporfin
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

NCT00247416
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
Gemcitabine, Dexamethasone, Carboplatin
Drug
Lead sponsor
Susanne Arnold
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
7
States / cities
Danville, Kentucky • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

NCT01282333
View directory record Official record
Conditions
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage III Pancreatic Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Bladder Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Pancreatic Cancer, Transitional Cell Carcinoma of the Bladder, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis, pharmacological study, cisplatin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Boston, Massachusetts • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC

NCT00621049
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Docetaxel/Carboplatin/Bevacizumab/Erlotinib, Docetaxel/Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
26
States / cities
Anniston, Alabama • Jonesboro, Arkansas • Fort Myers, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated No phase listed Observational

HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors

NCT05124743
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer
Interventions
Not listed
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

NCT05451849
View directory record Official record
Conditions
Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Ovarian Adenocarcinoma, Pancreatic Neoplasms, Colorectal Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Non Small Cell Lung Cancer
Interventions
TC-510, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
TCR2 Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
San Franciso, California • Miami, Florida • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer

NCT01000025
View directory record Official record
Conditions
Lung Cancer
Interventions
PF-00299804, Placebo
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Arcadia, California • Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Cisplatin in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer or Lung Metastasis

NCT01014598
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Lung, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Cisplatin, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

NCT03819387
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
NBF-006
Drug
Lead sponsor
Nitto BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Beverly Hills, California • La Jolla, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

NCT01631552
View directory record Official record
Conditions
Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer
Interventions
Sacituzumab Govitecan-hziy (SG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
12
States / cities
Aurora, Colorado • New Haven, Connecticut • Newark, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 21, 2026, 10:58 AM EDT
Active, not recruiting Not applicable Interventional

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT04751747
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Computed Tomography, Contrast Agent
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT04551885
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Locally Advanced NSCLC Hyperfractionated RT

NCT03128008
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung (NSCLC)
Interventions
Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Results available

A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors

NCT01457417
View directory record Official record
Conditions
Multiple Myeloma, Solid Tumors, Non-Small Cell Lung Cancer
Interventions
DKN-01
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Scottsdale, Arizona • Albany, New York • Greenville, South Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers

NCT03184168
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 21, 2026, 10:58 AM EDT
Active, not recruiting Phase 1 Interventional

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

NCT04526691
View directory record Official record
Conditions
Advanced or Metastatic NSCLC
Interventions
Datopotamab deruxtecan, KEYTRUDA®, Carboplatin, Cisplatin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Scottsdale, Arizona • Duarte, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 21, 2026, 10:58 AM EDT
Withdrawn Phase 2 Interventional

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

NCT05935774
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Magnetic Resonance Imaging, Trabedersen (OT-101)
Biological · Procedure · Other + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 21, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer

NCT01839955
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
erlotinib hydrochloride, quinacrine dihydrochloride - Escalation dose, laboratory biomarker analysis, pharmacological study, quinacrine dihydrochloride - Extension dose
Drug · Other
Lead sponsor
Neelesh Sharma MD PhD
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 21, 2026, 10:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

NCT07145255
View directory record Official record
Conditions
Prostate Cancer Castration-resistant Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Lung Cancer (Non-Small Cell), Pancreas Cancer, Duct Cell Adenocarcinoma
Interventions
ADC
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Grand Rapids, Michigan • East Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 21, 2026, 10:58 AM EDT